Epidemiology and outcomes of hepatitis C infection in elderly US Veterans

Journal of Viral Hepatitis

Volumn 23, Issue 9, 2016, Pages 687-696

  El Serag, H B ^a   Kramer, J ^a,b   Duan, Z ^b   Kanwal, F ^a  

^a MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

automated data; cirrhosis; hepatocellular cancer; under diagnosis; Veterans Administration

Indexed keywords

ADULT; AFRICAN AMERICAN; AGE DISTRIBUTION; AGED; ANTIVIRAL THERAPY; ARTICLE; BLACK PERSON; CANCER INCIDENCE; CAUCASIAN; CHRONIC HEPATITIS C; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; DOSE RESPONSE; FEMALE; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MORTALITY; OUTCOME ASSESSMENT; PREVALENCE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR; SUSTAINED VIRAL RESPONSE; UNITED STATES; VERY ELDERLY; YOUNG ADULT;

EID: 84980315449     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/jvh.12533     Document Type: Article

References (17)

1. Edlin BR, Eckhardt BJ, Shu MA et al. Towards a more accurate estimate of the prevalence of hepatitis C in the United States. Hepatology 2015; 62: 1353–1363.
2. Armstrong GL, Wasley A, Simard EP et al. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med 2006; 144: 705–714.
3. Davis GL, Alter MJ, El-Serag H et al. Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression. Gastroenterology 2010; 138(513–21): 521.
4. Thabut D, Le CS, Thibault V et al. Hepatitis C in 6,865 patients 65 yr or older: a severe and neglected curable disease? Am J Gastroenterol 2006; 101: 1260–1267.
5. Altekruse SF, Henley SJ, Cucinelli JE et al. Changing hepatocellular carcinoma incidence and liver cancer mortality rates in the United States. Am J Gastroenterol 2014; 109: 542–553.
6. Ioannou GN, Beste LA, Green PK. Similar effectiveness of boceprevir and telaprevir treatment regimens for hepatitis C virus infection on the basis of a nationwide study of veterans. Clin Gastroenterol Hepatol 2014; 12: 1371–1380.
7. Backus LI, Gavrilov S, Loomis TP et al. Clinical Case Registries: simultaneous local and national disease registries for population quality management. J Am Med Inform Assoc 2009; 16: 775–783.
8. Kramer JR, Davila JA, Miller ED et al. The validity of viral hepatitis and chronic liver disease diagnoses in Veterans Affairs administrative databases. Aliment Pharmacol Ther 2008; 27: 274–282.
9. Backus LI, Boothroyd DB, Phillips BR et al. Predictors of response of US veterans to treatment for the hepatitis C virus. Hepatology 2007; 46: 37–47.
10. Backus LI, Boothroyd DB, Phillips BR et al. A sustained virologic response reduces risk of all-cause mortality in patients with hepatitis C. Clin Gastroenterol Hepatol 2011; 9: 509–516.
11. Lens S, Rincon D, Garcia-Retortillo M et al. Association Between Severe Portal Hypertension and Risk of Liver Decompensation in Patients With Hepatitis C. Clin Gastroenterol Hepatol: Regardless of Response to Antiviral Therapy, 2015.
12. Kanwal F, White DL, Tavakoli-Tabasi S et al. Many patients with interleukin 28B genotypes associated with response to therapy are ineligible for treatment because of comorbidities. Clin Gastroenterol Hepatol 2014; 12: 327–333.
13. Singal AG, El-Serag HB. Hepatocellular Carcinoma From Epidemiology to Prevention: translating Knowledge into Practice. Clin Gastroenterol Hepatol 2015; 13: 2140–2151.
14. Jacobson IM, Gordon SC, Kowdley KV et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med 2013; 368: 1867–1877.
15. Lawitz E, Mangia A, Wyles D et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013; 368: 1878–1887.
16. Schmidt WN, Nelson DR, Pawlotsky JM et al. Direct-acting antiviral agents and the path to interferon independence. Clin Gastroenterol Hepatol 2014; 12: 728–737.
17. Jesudian AB, de Jong YP, Jacobson IM. Emerging therapeutic targets for hepatitis C virus infection. Clin Gastroenterol Hepatol 2013; 11: 612–619.